Gilead Sciences Archives -

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate DS-1062,

AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer

https://pharmaphorum.com/news/az-and-daiichis-trop2-adc-shows-promise-in-first-line-lung-cancer/

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

News/ News/ R&D

Gilead snaps up MiroBio and its checkpoint agonists for $405m

Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a

Gilead snaps up MiroBio and its checkpoint agonists for $405m

https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/

News/ News/ News/ Oncology/ Sales and Marketing

Gilead Sciences’ push into oncology is paying off, as Veklury falters

Phil Taylor Gilead Sciences, Sales and Marketing, Tecartus, Trodelvy, Veklury, Yescarta 0 Comment

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching

Gilead Sciences’ push into oncology is paying off, as Veklury falters

https://pharmaphorum.com/news/gilead-sciences-push-into-oncology-is-paying-off-as-veklury-falters/

Radiology technician examens mammography test

Market Access/ News/ News/ News/ Oncology

NICE backs two new breast cancer drugs for NHS use

Phil Taylor breast cancer, Gilead Sciences, HEOR, NHS, NICE, Novartis, Oncology, Piqray, Trodelvy 0 Comment

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer

NICE backs two new breast cancer drugs for NHS use

https://pharmaphorum.com/news/nice-backs-two-new-breast-cancer-drugs-for-nhs-use/

News/ News/ News/ Oncology/ R&D

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo

Phil Taylor Amgen, AstraZeneca, Blincyto, Gilead Sciences, immuno-oncology, M&A, non-Hodgkin lymphoma, Oncology, Tecartus, TeneoTwo 0 Comment

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo

https://pharmaphorum.com/news/astrazeneca-agrees-1-3bn-deal-to-buy-oncology-player-teneotwo/

Market Access/ News/ News

Gilead tries again with twice-yearly HIV drug lenacapavir

Phil Taylor follicular lymphoma, Gilead Sciences, HIV, infectious disease, lenacapavir, Oncology, Rukobia, ViiV Healthcare, Yescarta 0 Comment

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to

Gilead tries again with twice-yearly HIV drug lenacapavir

https://pharmaphorum.com/news/gilead-tries-again-with-twice-yearly-hiv-drug-lenacapavir/

News/ News/ Oncology

ASCO22: Gilead makes case for Trodelvy in advanced breast cancer

Phil Taylor ASCO 2022, breast cancer, Gilead Sciences, Oncology, Trodelvy 0 Comment

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of

ASCO22: Gilead makes case for Trodelvy in advanced breast cancer

https://pharmaphorum.com/news/asco22-gilead-makes-case-for-trodelvy-in-advanced-breast-cancer/

Market Access/ News/ News/ News/ Oncology

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Phil Taylor CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta 0 Comment

Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of

Kymriah is first CAR-T cleared for follicular lymphoma in EU

https://pharmaphorum.com/news/kymriah-is-first-car-t-cleared-for-follicular-lymphoma-in-eu/

Trending

Gilead Sciences

Login